News & Views: Defining the most appropriate phenotypes in genome-wide association studies of COVID-19 is challenging, and two papers in @NatureGenet show how case-control definitions determine outcomes and downstream clinical utility of findings. https://t.co/XIKDwOFjuM
Our recent genome-wide analysis shows that levels of the ACE2 receptor influence COVID-19 risk. A genetic variant near the ACE2 gene decreases levels of the SARS-CoV-2 gateway receptor by 37% and infection risk by 40%. Read more about our recent discovery in @NatureGenet.
Really nice COVID-19 genetic study by @dalygene and colleagues via @covid19_hgi. Together with additional studies (link👇🏽), there is good support that blocking ACE2 "through antibodies or other mechanisms might prevent infection or severe disease."
https://t.co/tmoHiCQqG2
The Regeneron Genetics Center (RGC) has published new data that shows a protective association between a variant in the SARS-CoV-2 receptor (ACE2) and reduced risk of #COVID disease.